Anti-human cardiac troponin I antibody and applications thereof
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- DONGGUAN PENGZHI BIOTECH CO LTD
- Publication Date
- 2020-04-17
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the fields of biotechnology and medical technology, in particular to an anti-human cardiac troponin I antibody and its application. Background technique
[0002] Before the 1980s, the World Health Organization (WHO) has always regarded myocardial enzyme activity as one of the diagnostic criteria for acute myocardial infarction (AMI). In the late 1980s, researchers discovered that the sensitivity and specificity of troponin (Tn) was higher than that of phosphocreatine kinase (CK), phosphocreatine kinase isoenzyme (CK-MB), lactate dehydrogenation enzymes and biomarkers such as aspartate aminotransferase. Cardiac troponin (cTnI) exists only in the myocardium and is a marker of cardiomyocytes. Its abnormal changes can affect the systolic function of the heart, and can be used to diagnose myocardial necrosis and judge myocardial injury. It has become a sensitive and specific marker of myocardial cell injury. It is recognized as th...